Top in allergy/asthma: Tree nut immunotherapy; dupilumab for atopic dermatitis
Click Here to Manage Email Alerts
The safety profile of oral immunotherapy for tree nut allergies among preschoolers was comparable to that of peanut oral immunotherapy, according to recent study results.
Stephanie C. Erdle, MD, FRCPC, investigator and allergist at the University of British Columbia, BC Children’s Hospital, and colleagues recommended that tree nut oral immunotherapy (OIT) be offered instead of strict avoidance. It was the top story in allergy/asthma last week.
Another top story covered a study that found no significant association between dupilumab for atopic dermatitis and the development of emergent or recurrent cancer.
Read these and more top stories in allergy/asthma below:
Tree nut oral immunotherapy deemed safe, tolerable for preschoolers
OIT for tree nut allergies was safe and tolerable among a preschool population with results comparable to OIT for peanut allergy, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice. Read more.
Dupilumab not linked to short-term cancer development in patients with atopic dermatitis
Patients with atopic dermatitis treated with dupilumab did not experience any significantly increased risk for a primary or recurrent malignancy, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice. Read more.
Older patients with chronic urticaria present with unique characteristics
Older patients with chronic urticaria have characteristics that are unique compared with younger patients, such as high rates of autoimmunity and malignancy, according to a study. Read more.
Q&A: Sublingual immunotherapy safe, effective for children with peanut allergy
Sublingual immunotherapy for peanut allergy was safe and effective among children aged 2 to 12 years, making it a promising alternative to oral immunotherapy, according to a study published in The Journal of Allergy and Clinical Immunology. Read more.
Multiple obstacles make hereditary angioedema diagnosis, treatment difficult
Clinical and economic factors make hereditary angioedema difficult to diagnose and treat, particularly among patients who live in rural areas, according to a study published in Annals of Allergy, Asthma & Immunology. Read more.